Source: International Congress 2018 – Clinical aspects of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Savale (Le Kremlin-Bicêtre, France), N. Ebstein (Le Kremlin-Bicêtre, France), M. Jevnikar (Le Kremlin-Bicêtre, France), X. Jaïs (Le Kremlin-Bicêtre, France), F. Parent (Le Kremlin-Bicêtre, France), A. Boucly (Le Kremlin-Bicêtre, France), G. Simonneau (Le Kremlin-Bicêtre, France), D. Montani (Le Kremlin-Bicêtre, France), M. Humbert (Le Kremlin-Bicêtre, France), O. Sitbon (Le Kremlin-Bicêtre, France). Survival in portopulmonary hypertension (PoPH) in the era of modern PAH-targeted therapy. 3081

Member's Comments

No comment yet.

Related content which might interest you: Ambrisentan for therapy of portopulmonary hypertension (POPH): Update on safety and efficacy Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Survival of patients with schistosomiasis-associated pulmonary arterial hypertension in the modern management era Source: Eur Respir J, 51 (6) 1800307; 10.1183/13993003.00307-2018 Year: 2018 Pulmonary arterial hypertension: combination therapy in the modern management era Source: Eur Respir Rev 2010 19: 348-349 Year: 2010 Long-term outcome of sarcoidosis-associated pulmonary hypertension in the modern treatment era Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Survival in patients with chronic thromboembolic pulmonary hypertension in the modern management era Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020 Survival with first-line bosentan in patients with primary pulmonary hypertension. Source: Eur Respir J 2005; 25: 942 Year: 2005 Long-term outcome of patients with portopulmonary hypertension treated with sildenafil Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Sildenafil treatment for portopulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 651s Year: 2006 Factors associated with survival in patients with not-operated chronic thromboembolic pulmonary hypertension (CTEPH) in the modern management era Source: International Congress 2018 – Chronic thromboembolic pulmonary hypertension Year: 2018 Safety and efficacy of immunoadsorption as an add-on to medical treatment in patients with idiopathic pulmonary arterial hypertension Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 How should we treat portopulmonary hypertension? Source: Eur Respir J 2006; 28: 466-467 Year: 2006 Pregnancy outcomes in pulmonary arterial hypertension in the modern management era Source: Eur Respir J 2012; 40: 1304-1305 Year: 2012 Iloprost treatment in portopulmonary hypertension Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008 Development of hepatopulmonary syndrome during combination therapy for portopulmonary hypertension Source: Eur Respir J, 53 (1) 1801880; 10.1183/13993003.01880-2018 Year: 2019 Time to combination therapy for sildenfail monotherapy in pulmonary artery hypertension (PAH). A comparison with the reported experience with bosentan Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Sildenafil for patients with portopulmonary hypertension, candidates to hepatic transplant Source: Eur Respir J 2004; 24: Suppl. 48, 109s Year: 2004 Challenges in the diagnosis and treatment of pulmonary arterial hypertension Source: Eur Respir Rev 2012 21: 313-320 Year: 2012 Sequential multimodal therapy in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020 Combination therapy with sildenafil and sitaxentan therapy for pulmonary arterial hypertension Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous Year: 2008 Pulmonary arterial hypertension: tailoring treatment to risk in the current era Source: Eur Respir Rev, 26 (146) 170095; 10.1183/16000617.0095-2017 Year: 2017